0855167 | FITC IgG Goat Anti-Human Complement C3 2 mL | MPBIO
Key Features and Details
Lyophilized fluorescein-5-isothiocyanate (FITC “Isomer I”)-conjugated goat IgG fraction to human complement C3 and buffer salts.
SKU | 0855167 |
Antibody Type | Polyclonal Antibody |
Application Notes | Fluorescein-conjugated Goat IgG Fraction to Human Complement C3 is used as a reagent in immunofluorescence assays (IFA), cell staining (fluorescent microscopy and cell sorting) and tissue staining. Note: F(ab’)2 fragments are recommended for staining of cells or tissues which contain Fc receptors). It is also used for Immunohistochemistry techniques at a dilution of 1:50. |
Base Catalog Number | 55167 |
Conjugate | FITC |
Format | lyophilized |
Formulation Details | Lyophilized |
Grade | Molecular Grade |
Host | Goat |
Immunogen | Human C3 purified from serum |
Pack Size | 2 mL |
Preparation Method | Antibody and FITC are conjugated under defined conditions to obtain the specified molar ratio (3-6 mol/mol). Conjugated protein is purified by gel filtration. The product is dialyzed into 0.02M sodium phosphate, 0.14M sodium chloride, pH 7.3, with 0.05% sodium azide, adjusted to standard titer, filtered through a 0.22 μm filter, vialed, and lyophilized. |
Purity | Purified |
Solubility | Reconstitution: Reconstitute product with 2.0 mL of deionized or distilled water. Gentle swirling may be used to speed rehydration. Avoid vigorous shaking of the reconstituted material. |
Species Reactivity | Human |
Specificity | This product shows reactivity to human complement C3; cross-reactivity to other species may exist. Antibody activity to complement components C4-C9 or serum proteins is not present. |
Typical Working Concentration | Dilution Recommendations: 1:100 – 1:400 for Tissue Staining; 1:1,000 – 1:4,000 for ELISA/FIA |
Usage Statement | Unless specified otherwise, MP Biomedical’s products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department. |